Tìm theo
Secukinumab
Các tên gọi khác (1) :
  • AIN457
Thuốc Gốc
Biotech
CAS: 875356-43-7
CTHH: C6584H10134N1754O2042S44
PTK: 147.94 kDa
A human monoclonal antibody, secukinumab (Cosentyx) was designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A inhibitor marketed by Novartis. On January 19, 2015, secukinumab was approved by the European Commission as a first line systemic treatment in moderate to severe adult plaque psoriasis. On January 21, 2015, the United States Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6584H10134N1754O2042S44
Phân tử khối
147.94 kDa
Liều Lượng & Cách Dùng : Injection - Subcutaneous - 300 mg
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty : Novartis
    Sản phẩm biệt dược : Cosentyx
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB09029
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D09967
Wikipedia
http://en.wikipedia.org/wiki/Secukinumab
... loading
... loading